AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01390545
Drug: Veltuzumab
RxNorm normalized name: Veltuzumab
DrugBank: Veltuzumab (DB05656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
Trial: NCT00100048
Drug: Comparator: efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efavirenz 600 mg every night at bedtime for 48 weeks
Trial: NCT00100048
Drug: Comparator: tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tenofovir 300 mg daily for 48 weeks
Trial: NCT00100048
Drug: Comparator: lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine 300 mg daily for 48 weeks
Trial: NCT00876642
Drug: Aloe vera gel
RxNorm normalized name: ALOE VERA GEL
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
Trial: NCT04992988
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT
Trial: NCT03050164
Drug: Gefitinib Tablet 250mg of Hunan Kelun
RxNorm normalized name: gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
Trial: NCT03597464
Drug: Voclosporin
RxNorm normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
Trial: NCT02302495
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study.
Trial: NCT00003400
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003400
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003400
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003400
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03722875
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
Trial: NCT02128061
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02128061
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00120003
Drug: Candesartan Cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
Trial: NCT03722875
Drug: apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib is a selective VEGFR2 inhibitor
Trial: NCT03058744
Drug: Ultravate Cream
RxNorm normalized name: halobetasol Topical Cream [Ultravate]
DrugBank: Ulobetasol (DB00596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream
Trial: NCT03058744
Drug: Tazorac Cream
RxNorm normalized name: tazarotene Topical Cream [Tazorac]
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream
Trial: NCT00609622
Drug: sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
Trial: NCT00609622
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
Trial: NCT01027117
Drug: Revatio
RxNorm normalized name: Revatio
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
Trial: NCT01696461
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01053429
Drug: ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
Trial: NCT00825370
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
Trial: NCT01708057
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium administered via inhalation
Trial: NCT03866200
Drug: resveratrol
RxNorm normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/day or 5 ml once per day for 90 days
Trial: NCT00947349
Drug: ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ribavirin (RBV)
Trial: NCT00947349
Drug: pegylated interferon (PegIFN) alfa-2a
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated interferon (PegIFN) alfa-2a
Trial: NCT00947349
Drug: BI 201335 NA high
RxNorm normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BI 201335 NA high
Trial: NCT00947349
Drug: BI 201335 NA low
RxNorm normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BI 201335 NA
Trial: NCT02544776
Drug: Clomifene citrate ( clomid 50 mg )
RxNorm normalized name: clomifene
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02544776
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00538681
Drug: enzastaurin
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression
Trial: NCT00538681
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
Trial: NCT00538681
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m², IV, every 21 days, for each 21-day cycle
Trial: NCT01209715
Drug: Fluticasone /salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
Trial: NCT00302640
Drug: Alinia (nitazoxanide)
RxNorm normalized name: nitazoxanide Oral Suspension [Alinia]
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01587950
Drug: Potassium Nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 250 μL of Potassium nitrate solution (either 5% or 2.5%)
Trial: NCT01662999
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01662999
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03700099
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.
Trial: NCT03700099
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.
Trial: NCT01322815
Drug: chemotherapy and GI-4000
RxNorm normalized name: GI-4000
DrugBank: GI-4000 (DB05698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks
Trial: NCT01322815
Drug: GI-4000
RxNorm normalized name: GI-4000
DrugBank: GI-4000 (DB05698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
Trial: NCT04580147
Drug: Intravitreal aflibercept injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
Trial: NCT01511757
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole Tablets, 200 mg
Trial: NCT01511757
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluconazole 200 mg
Trial: NCT02932267
Drug: Adapalene 0.3% / BPO 2.5% gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
Trial: NCT03200951
Drug: Bolus group for epidural block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
Trial: NCT03200951
Drug: Infusion group for epidural block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
Trial: NCT01245647
Drug: Naltrexone, 50mg, once per day for 4 months
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
Trial: NCT00342355
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg once daily
Trial: NCT00342355
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg once daily
Trial: NCT00342355
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \<60 kg/125 mg twice daily or \>60kg/200 mg twice daily
Trial: NCT00342355
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg once daily
Trial: NCT00342355
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg once daily
Trial: NCT00342355
Drug: Lopinavir/Ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: r/LPV 400mg/100mg twice daily
Trial: NCT00433888
Drug: R744
RxNorm normalized name: Remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
Trial: NCT00433888
Drug: R744
RxNorm normalized name: Remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
Trial: NCT02489214
Drug: donafenib tosilate tablets
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg bid
Trial: NCT01466244
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01037309
Drug: PRO044 SC
RxNorm normalized name: PRO044
DrugBank: BMN-044 (DB17003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection, once a week, for five weeks
Trial: NCT01037309
Drug: PRO044 IV
RxNorm normalized name: PRO044
DrugBank: BMN-044 (DB17003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection, once a week, for five weeks
Trial: NCT01526356
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study cream is applied nightly to the affected areas on the face. Low Dose
Trial: NCT01526356
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study cream is applied nightly to the affected areas on the face. High Dose
Trial: NCT03751332
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
Trial: NCT04421300
Drug: 0.1% sodium hyaluronate eye drop
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.
Trial: NCT00009737
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 425mg/m2 iv daily from day 1 to day 5 every 28 days.
Trial: NCT03219164
Drug: AZLI
RxNorm normalized name: Bazlitoran
DrugBank: Bazlitoran (DB14990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
Trial: NCT00313274
Drug: Clevudine
RxNorm normalized name: clevudine
DrugBank: Clevudine (DB06683)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00960076
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg oral tablet once daily
Trial: NCT00960076
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg oral tablet once daily
Trial: NCT00960076
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 750mg, 2 tablets once daily
Trial: NCT01711463
Drug: Fluticasone Furoate/Vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
Trial: NCT01431287
Drug: tiotropium + olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed dose combination
Trial: NCT01431287
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose or high dose
Trial: NCT01431287
Drug: olodaterol
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one dose only
Trial: NCT02714179
Drug: Paracetamol was given intravenously in both group at different times
RxNorm normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04025632
Drug: zilucoplan
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous (SC) inection
Trial: NCT02087332
Drug: Prolonged release Torasemide (Britomar)
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02087332
Drug: Torasemide (Diuver)
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03990129
Drug: Metamizole
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One week treatment with metamizole (500 mg tablets, 2-2-2)
Trial: NCT03426137
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg Oxycodone in oral solution given every 3 hours
Trial: NCT00376961
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3 mg/m\^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
Trial: NCT00376961
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg on days 1-5 of cycles 1-6.
Trial: NCT00376961
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m\^2 on day 1 of cycles 1-6.
Trial: NCT00618722
Drug: Deoxycholic Acid Injection
RxNorm normalized name: deoxycholic acid Injection
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03027167
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00460993
Drug: Lunesta
RxNorm normalized name: Lunesta
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4.
Trial: NCT00334659
Drug: apricitabine
RxNorm normalized name: Apricitabine
DrugBank: Apricitabine (DB12855)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02815111
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive an analgesic regimen that involves Ketamine infusions
Trial: NCT02815111
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive an analgesic regimen that involves Lidocaine infusions
Trial: NCT02815111
Drug: Neurontin
RxNorm normalized name: Neurontin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: May be given Neurontin by mouth as an approved medication for pain control
Trial: NCT00710333
Drug: Avotermin
RxNorm normalized name: avotermin
DrugBank: Avotermin (DB11955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
Trial: NCT02829034
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Trial: NCT00000264
Drug: 30% Nitrous oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02561897
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02561897
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00170976
Drug: valsartan + amlodipine
RxNorm normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01059448
Drug: AMG 827
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 827 210 mg
Trial: NCT01969721
Drug: fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: low dose
Trial: NCT01969721
Drug: salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03429218
Drug: TP-0184
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral dose once weekly for 4 weeks